

NAVIGATING THE EVOLVING BLADDER CANCER LANDSCAPE

The Nurse's Role in
Improving Patient Outcomes



Presented by Creative Educational Concepts, LLC.
Supported through independent educational grants from AstraZeneca and Merck.



Tara Cumming, NP
Acute Care Nurse
Practitioner, Urology
Texas Urology Group
San Antonio, TX

Meet the Faculty



Terran W. Sims MSN, ACNP-C, CNN, COCN-C
GU Oncology Nurse Practitioner
University of Virginia Health System
Department of Urology
Charlottesville, VA

Faculty Disclosures

It is the policy of Creative Educational Concepts, LLC, (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers' bureaus, other benefits, or having a self-managed equity interest in a company.

CEC has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Planners/Faculty:

Tara Cumming, APRN—has disclosed that she receives salary/employment from Texas Urology Group and is an advisor or consultant to Photocure.
Terran W. Sims, MSN, ACNP-C—has disclosed that she is an advisor or consultant to Coloplast.

Peer Reviewer:

Caroline Pratz, CRNP—has no relevant financial relationships to disclose in relation to the content of this activity.

CEC Staff/Planners:

Susan H. Gitzinger, PharmD, MPA—has no relevant financial relationships to disclose in relation to the content of this activity.
Bryan C. Taylor, PharmD—has no relevant financial relationships to disclose in relation to the content of this activity.
Jessica Hall—has no relevant financial relationships to disclose in relation to the content of this activity.

Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CEC, the faculty, and any commercial supporter of this activity do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Thank You

Presented by Creative Educational Concepts



*Supported through independent educational grants from
AstraZeneca and Merck*

Learning Objectives

- Appraise the expanding clinical trial evidentiary base across all stages of the bladder cancer disease continuum, including newly-approved indications, recently-reported data, and current consensus guideline recommendations for treatment of NMIBC, MIBC, and locally advanced/mUC.
- Examine the evolving bladder cancer management calculus, with a focus on evidence-based treatment sequencing strategies and/or combinatorial regimens incorporating platinum chemotherapy, immune checkpoint inhibitors, targeted therapies, and antibody-drug conjugates.
- Review practical patient counseling strategies related to the safety, efficacy, and therapeutic rationale of novel treatments in bladder cancer, with an emphasis on the provision of adaptive emotional support infrastructures.
- Identify immune-mediated adverse events (imAEs) that may occur in patients with bladder cancer receiving immune checkpoint inhibitors, either as monotherapy or in combination, and implement adaptive imAE anticipation, recognition, and management strategies.

Accreditation

- Nurses: 1.0 ANCC contact hour:

<https://www.surveymonkey.com/r/C292VQP>

